{"Signatur": "CH_PATG_001", "Spider": "CH_BPatG", "Datum": "2017-08-29", "PDF": {"Datei": "CH_BPatG/CH_PATG_001_O2015-012_2017-08-29.pdf", "URL": "https://www.bundespatentgericht.ch/fileadmin/entscheide/O2015_012_Urteil_2017-08-29.pdf", "Checksum": "2043fdbef6fc21d3bd5dda356cb69bfa"}, "Scrapedate": "2026-04-05", "Num": ["O2015_012"], "Kopfzeile": [{"Sprachen": ["de"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}, {"Sprachen": ["fr"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}, {"Sprachen": ["it"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}], "Meta": [{"Sprachen": ["de"], "Text": "Eidgenossenschaft Bundespatentgericht "}, {"Sprachen": ["fr"], "Text": "Conféderation Bundespatentgericht "}, {"Sprachen": ["it"], "Text": "Confederazione Bundespatentgericht "}], "Abstract": [{"Sprachen": ["de", "fr", "it"], "Text": "Gutheissung Nichtigkeitsklage; Nichtzulassung verspäteter Einschränkung | Erfinderische Tätigkeit, Fachmann, Fachrichtervotum, Feststellungsklage, Kosten: Parteientschädigung, Lugano Übereinkommen, Neuheit, Örtliche Zuständigkeit national, Sistierung auf Antrag der Parteien, Unzulässige Änderung (Art. 123(2) EPÜ)"}], "ScrapyJob": "446973/64/2135", "Zeit UTC": "05.04.2026 03:17:34", "Checksum": "4d0a177484cbfebda55371720bbcce45", "Chunktext": "Auszug aus dem Entscheid Bundespatentgericht 29.08.2017 O2015_012\nRegeste:\nGutheissung Nichtigkeitsklage; Nichtzulassung verspäteter Einschränkung | Erfinderische Tätigkeit, Fachmann, Fachrichtervotum, Feststellungsklage, Kosten: Parteientschädigung, Lugano Übereinkommen, Neuheit, Örtliche Zuständigkeit national, Sistierung auf Antrag der Parteien, Unzulässige Änderung (Art. 123(2) EPÜ)\n\n prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.\n3. The use as claimed in claim 1 or 2, wherein the blood plasma\nfulvestrant concentration attained is at least 2.5 ngml-1 for at\nleast 2 weeks.\n4. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical\nformulation comprises fulvestrant in solution, 30% or less\nweight of a pharmaceutically-acceptable alcohol per volume of\nformulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate\nvehicle per volume of formulation and a sufficient amount of a\nricinoleate vehicle so as to prepare a formulation of at least 45\nmgml-1 of fulvestrant.\nwith dependent claims 5 to 17 to remain unchanged and claims\n18. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical\nformulation comprises fulvestrant in solution,15-25 % weight of\na pharmaceutically-acceptable alcohol per volume of formulation, 10-25 % weight of a pharmaceutically-acceptable nonaqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1 of fulvestrant.\n19. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical\nformulation comprises fulvestrant in solution, 17-23% weight of\na pharmaceutically-acceptable alcohol per volume of formulation, 12-18% weight of pharmaceutically-acceptable nanaqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1 of fulvestrant.\nwith dependent claims 20 to 22 to remain unchanged and claims\n\nSeite 6\nO2015_012\n\n23. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical\nformulation comprises fulvestrant in solution,15-25% weight of\na pharmaceutically-acceptable alcohol per volume of formulation, 10-25% weight of benzyl benzoate in a ricinoleate vehicle\nper volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1\nof fulvestrant.\n24. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical\nformulation comprises fulvestrant in solution,17-23 % weight of\na pharmaceutically-acceptable alcohol per volume of formulation, 12-18% weight of benzyl benzoate in a ricinoleate vehicle\nper volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1\nof fulvestrant.\nwith dependent claims 25 to 31 to remain unchanged.\n4. Auxiliary to no. 3 above, the Patent is to be upheld with the following\nlimited claims:\n1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the formulation comprises fulvestrant dissolved in a ricinoleate vehicle, a pharmaceutically acceptable alcohol consisting of a mixture of 10%\nweight of ethanol per volume of formulation and 10% weight\nbenzyl alcohol per volume of formulation and 15% weight benzyl benzoate per volume of formulation wherein the ricinoleate\nvehicle is castor oil and the formulation is adapted for attaining\na therapeutically significant blood plasma fulvestrant concentration of at least 8.5 ngml-1.\n2. The use as claimed in claim 1, whereas the formulation is present in a syringe or vial.\n5. Auxiliary to no. 4 above, the Patent is to be upheld with the following\nlimited claims:\n1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular ad-\n\nSeite 7\nO2015_012\n\n"}